Top Injectable Manufacturer in Puerto Rico – Reliable Pharmaceutical Solutions
- Maulik Sudani
- 6 days ago
- 13 min read
Last Updated: August 31, 2026
TL;DR: Puerto Rico is not a sovereign regulatory jurisdiction, and almost everything written about supplying it gets that half-right in a way that costs money. There is no Puerto Rican marketing authorisation to win: medicines are approved by the US FDA under the Federal Food, Drug, and Cosmetic Act, whose definition of “State” includes the Commonwealth, so the entry ticket is an ANDA or 505(b)(2) plus an FDA-inspected plant. But it is equally wrong to conclude that nothing local applies. Reglamento 156B, made under the Ley de Farmacia de Puerto Rico, forbids displaying, offering, distributing, selling, delivering, storing, donating or promoting any medicine on the island unless it is registered with the Department of Health, at USD 25 per registration transaction, and that registration can only be made by a licensed manufacturer or distributor or a certified resident representative agent. The commercial reality behind both facts is starker still: Puerto Rico exported USD 48.3 billion of pharmaceuticals in FY2024 to a population of about 3.18 million and falling. It is a competitor before it is a customer. This guide sets out what is verified, what we could not read, and where the real opportunity for an Indian sterile injectable maker actually sits.
Key Takeaways
There is no Puerto Rican drug approval to obtain. Product authorisation is US FDA under the FD&C Act — ANDA under section 505(j), 505(b)(2), NDA or BLA, with a Type II DMF for the API, establishment registration and drug listing under section 510, and a mandatory US agent under 21 CFR 207.69(b) who must reside or keep a place of business in the United States. FDA has no GMP mutual-recognition arrangement with India; the only pharmaceutical MRA of that kind is with the European Union. WHO-GMP certification and CDSCO approval carry no recognition weight with FDA, so every site must be inspected by FDA itself, and FDA has extended unannounced foreign inspections building on a pilot run in India and China.
But FDA approval alone is not enough to sell there, and this is the error that costs money. Article 3.01 of Reglamento 156B, made under Ley 247-2004, prohibits any person in Puerto Rico from displaying, offering for sale, distributing, selling, delivering, storing, giving away or promoting any medication, prescription or over-the-counter, unless it has been registered with the Department of Health. The fee is USD 25 per registration transaction or change. Establishment licences run to USD 1,500 for pharmaceutical industry, USD 500 for a non-prescription wholesale distributor and USD 250 for biological products. Registration is administered by the División de Medicamentos y Farmacias. Confirm the schedule before budgeting: the regulation dates from 2020 and we could not verify that the fees are unchanged in 2026.
The structural cost gap is written into United States statute and it is permanent. The GDUFA fee notices for both FY2026 and FY2027 apply a USD 15,000 surcharge to facilities located outside “the United States and its territories and possessions”. Puerto Rico is inside that perimeter, so a plant on the island pays the domestic rate while a plant in Gujarat pays the foreign one. For FY2027, effective 1 October 2026, a foreign finished-dosage facility pays USD 245,033, a foreign API facility USD 54,680, a foreign contract manufacturing facility USD 70,208, an ANDA filing USD 375,684 and a Type II DMF USD 109,899. Being inside the United States customs territory has the same consequence for trade: there is no India–Puerto Rico trade line, no separate tariff and no separate import licence.
The honest strategic reading is that Puerto Rico is a competitor first. Government figures put pharmaceutical exports at USD 48,328 million in FY2024, seventy-four per cent of the island’s total exports, produced by 13,197 people across 60 establishments and more than fifty FDA-approved plants, against a resident population the Census Bureau estimated at 3,184,835 on 1 July 2025 and falling. The opening for an Indian sterile injectable maker is not market entry but United States supply resilience: when Hurricane Maria disabled Baxter’s island capacity in 2017 and worsened a national intravenous fluid shortage, FDA opened the door to foreign sterile supply. That concentration risk has not gone away.
Introduction: Why Puerto Rico Demands a Premium Injectable Manufacturer in Puerto Rico
Puerto Rico is the most misunderstood entry on any pharmaceutical export map, and the misunderstanding runs in both directions. It is an unincorporated territory of the United States, inside the United States customs territory, and the Federal Food, Drug, and Cosmetic Act defines “State” to include the Commonwealth of Puerto Rico. The consequence is immediate and non-negotiable: there is no Puerto Rican dossier to compile, no local efficacy review, no island marketing authorisation, and no Common Technical Document filed in San Juan. A supplier who arrives looking for the Puerto Rican equivalent of a national medicines agency will not find one, because it does not exist. Any content that describes a Puerto Rican drug registration procedure with dossier modules and review timelines is describing something imaginary, and we would rather say so plainly than reproduce it. The product pathway is the ordinary United States one, and it is demanding on its own terms: an abbreviated new drug application under section 505(j), or a 505(b)(2) or full new drug application where the product warrants it, supported by a Type II drug master file for the active ingredient, establishment registration and drug listing under section 510, and a designated United States agent under 21 CFR 207.69(b) who must reside or maintain a place of business in the United States and cannot be a mailbox or an answering service.
The opposite error is the more expensive one, and it is the reason this article exists in the form it does. It does not follow from federal jurisdiction that nothing local applies. Reglamento 156B, an amendment to Reglamento 156 made under Ley 247-2004, the Ley de Farmacia de Puerto Rico, imposes a genuine island-level regime on top of FDA approval, and its article 3.01 is expressed as a prohibition rather than a formality: no person in Puerto Rico may display, offer for sale, distribute, sell, deliver, store, give away or donate, or promote in any way, any medication for use in humans or animals unless that medication has been registered with the Department. Note that storage is in the list. The fee is modest, USD 25 for each registration transaction or change to registered information, and the administering body is the División de Medicamentos y Farmacias within the Secretaría Auxiliar para la Regulación de la Salud Pública, which also handles establishment licensing, certificates of origin, free-sale certificates and good manufacturing practice matters. Two things separate this from an administrative detail: registration may only be performed by a duly licensed manufacturer or distributor, or delegated after notice to a certified resident representative agent, and the Department maintains a distinct process for non-resident distributors that we will come to, because what we could not read about it matters as much as what we could.
What Sets a World-Class Injectable Manufacturer in Puerto Rico Apart
The first thing that separates a serious supplier here is understanding that Indian regulatory credentials buy nothing at the federal door. The United States Food and Drug Administration operates one pharmaceutical good manufacturing practice mutual-recognition arrangement of consequence, and it is with the European Union: the sectoral annex entered into force on 1 November 2017 and capability assessments for all European Union human-drug authorities were completed on 11 July 2019, with further arrangements covering Switzerland and the United Kingdom. No Indian authority appears anywhere in that framework. WHO-GMP certification, CDSCO approval and Indian Schedule M compliance therefore carry precisely zero recognition weight with FDA, and every site intended to supply the United States market, Puerto Rico included, must be inspected by FDA itself. FDA has moreover announced an expanded use of unannounced inspections at foreign manufacturing facilities, building explicitly on a foreign unannounced inspection pilot conducted in India and China, which means an Indian plant should treat the unannounced inspection as the base case rather than the exception. A quality system that is genuinely inspection-ready on any working day, rather than one that is assembled in the fortnight before a scheduled visit, is the difference between a viable United States programme and a costly one.
The second differentiator is arithmetic, and it is uncomfortable. The generic drug user fee structure surcharges foreign facilities by statute. Both the FY2026 and the FY2027 Federal Register notices set the differential for facilities located outside “the United States and its territories and possessions” at USD 15,000, and because Puerto Rico sits inside that perimeter a plant on the island pays the domestic rate while a plant in Gujarat does not. In FY2026, in force until 30 September 2026, an ANDA filing costs USD 358,247, a Type II drug master file USD 102,584, a foreign finished-dosage facility USD 253,943, a foreign active ingredient facility USD 58,549 and a foreign contract manufacturing facility USD 72,346. From 1 October 2026 the FY2027 rates apply: ANDA USD 375,684, drug master file USD 109,899, foreign finished-dosage facility USD 245,033, foreign active ingredient facility USD 54,680, foreign contract manufacturing facility USD 70,208. Programme fees run from USD 192,729 for a small business to USD 1,927,291 for a large operation in FY2027. None of this is negotiable and none of it is temporary, so it belongs in the business case at the outset rather than as a surprise in year one. The third differentiator is supply-chain data: the Drug Supply Chain Security Act is federal and applies in Puerto Rico exactly as in any state, with no territorial carve-out, and a foreign manufacturer is already fully in scope, so serialised package-level data and interoperable electronic transaction records must flow to the United States importer from the first shipment.
Quality Systems Behind Every Injectable Supplied to Puerto Rico
On the island-level requirements we want to be exact about the boundary between what we verified and what we could not, because this is where a confident-sounding answer would be worth less than an honest one. What is verified is the prohibition in article 3.01, the USD 25 registration fee at article 3.04(h), the rule that registration is performed by a licensed manufacturer or distributor or by a certified resident representative agent, and the establishment licence fees at article 2.03. What we could not establish is the single most important operational question for a foreign manufacturer: whether you must yourself hold a Puerto Rico licence, or whether the obligation rests wholly on your licensed local distributor. Article 3.01 attaches the duty to persons in Puerto Rico and article 3.04 says registration will be performed by duly licensed manufacturers or distributors, which reads naturally as putting the filing in your distributor's hands. But the Department publishes notices addressed specifically to non-resident distributors, in both Spanish and English, and those documents are image-only scans with no machine-readable text. We could not read them. They are exactly where this question would be resolved, and we will not guess at their contents. Settle it directly with the División de Medicamentos y Farmacias or with Puerto Rico counsel before you commit to a structure.
A second open point compounds the first. The Department has issued an administrative order extending a moratorium on licences for representative agents of manufacturers or distributors of medications. We did not open that order and cannot confirm whether the moratorium remains in force in 2026. If it does, it may close off the very delegation route that article 3.04 otherwise contemplates, forcing reliance on an already-licensed distributor rather than on an agent appointed for the purpose. That is a structural question with commercial consequences and it should be asked before a distribution agreement is signed, not after. For controlled substances, federal Drug Enforcement Administration registration applies and Puerto Rico separately enforces its own controlled substances law of 1971, though for a general sterile injectable portfolio this is usually out of scope. We should also be candid about what this article does not contain: we researched no Puerto Rican disease-burden data at all. There is no diabetes, chronic kidney disease, dialysis or oncology figure here, no hospital or bed count, and no health expenditure number, because none was obtained. Assertions about the island’s clinical demand profile are common in supplier content and we are not going to add to them without a source.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Injectable Manufacturer in Puerto Rico for Global Buyers
Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO based in Gujarat, India, filling under ISO Class 5 conditions and supplying more than thirty export markets. We work across dry powder and liquid vials, ampoules and lyophilised presentations, with analytical control built on HPLC, GC, Karl Fischer titration and LAL bacterial endotoxin testing, and stability programmes designed to ICH Q1A and Q1B. We prepare documentation in CTD, ACTD and eCTD formats according to what the destination authority actually asks for, and we maintain drug master files where a market requires them. For a United States programme, including Puerto Rico, we are clear-eyed that this portfolio is a starting point and not a passport: it is the platform on which an FDA submission and an FDA inspection are built, not a substitute for either.
What we bring to a Puerto Rico conversation is a refusal to sell the easy version of it. A partner who tells you that FDA approval is all you need has not read Reglamento 156B; a partner who offers to walk you through Puerto Rican dossier submission has invented a procedure that does not exist. We would rather set out the two-layer structure accurately, name the fee schedule with the caveat that it dates from 2020, tell you which documents we could not read, and let you take advice on the points that turn on them. That approach has a practical payoff as well as an ethical one, because the questions we are flagging — whether the foreign manufacturer needs its own licence, and whether the representative agent moratorium still bites — are precisely the ones that determine whether your route to the island runs through an agent or through a distributor, and that decision is expensive to reverse.
The larger strategic point is the one we would put to any buyer considering this market, and it reframes the question. Puerto Rico produced USD 48,328 million of pharmaceutical exports in fiscal year 2024, seventy-four per cent of everything the island exports, from 60 establishments employing 13,197 people, with pharmaceutical manufacturing contributing roughly thirty per cent of gross domestic product and more than fifty FDA-approved plants on the island. The resident population was estimated at 3,184,835 on 1 July 2025, down about ninety-seven thousand since the 2020 census. Three million people cannot absorb forty-eight billion dollars of output; the island is an export platform aimed at the United States mainland, which is the same customer an Indian exporter is aiming at. The island does import, and substantially — USD 16,805 million in FY2024, of which USD 6,503 million came from foreign countries, led by Ireland, Singapore, Portugal and Italy, with India inside the residual category. But the sharper opportunity is resilience. When Hurricane Maria took out power at Baxter’s Puerto Rico plants in September 2017 and materially worsened a national shortage of intravenous saline and amino acid injections, FDA responded by not objecting to temporary imports from Ireland, Australia, Mexico, Canada and Germany and by clearing additional suppliers. That is the best-documented precedent for FDA using regulatory discretion to admit foreign sterile injectable supply during a United States shortage, and the concentration of sterile injectable and biologic capacity on a hurricane-exposed island has not changed since. An ANDA portfolio in shortage-listed sterile injectables, filed and inspected in advance, is a more realistic plan than a Puerto Rico market-entry strategy.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Do I need a separate Puerto Rico drug registration, or is FDA approval enough?
Both, and this catches people out. There is no Puerto Rican marketing authorisation — product approval is US FDA under the Federal Food, Drug, and Cosmetic Act, which defines “State” to include the Commonwealth. But article 3.01 of Reglamento 156B, made under Ley 247-2004, separately prohibits displaying, offering for sale, distributing, selling, delivering, storing, giving away or promoting any medication in Puerto Rico unless it has been registered with the Department of Health, at USD 25 per registration transaction. FDA approval is necessary but not sufficient. The two are different things: FDA decides whether the drug may be marketed, the Department of Health decides whether it may be sold on the island.
Must an Indian manufacturer itself hold a Puerto Rico licence?
We do not know, and we would rather say so than guess. Article 3.01 attaches the duty to persons in Puerto Rico and article 3.04 provides that registration is performed by duly licensed manufacturers or distributors, or by a certified resident representative agent, which reads naturally as placing the filing with your licensed local distributor. But the Department publishes notices addressed specifically to non-resident distributors, in Spanish and English, and both are image-only scans that we could not read. That is precisely where this would be settled. There is also an administrative order extending a moratorium on representative agent licences whose current force we could not confirm, and which may close the delegation route. Take this to the División de Medicamentos y Farmacias or to Puerto Rico counsel before choosing a structure.
Does our WHO-GMP certificate help with FDA?
No. FDA operates one pharmaceutical GMP mutual-recognition arrangement of this kind and it is with the European Union, in force from 1 November 2017 with capability assessments for all European Union human-drug authorities completed on 11 July 2019, plus arrangements with Switzerland and the United Kingdom. No Indian authority appears in that framework. WHO-GMP certification and CDSCO approval carry no recognition weight with FDA, and every site must be inspected by FDA itself. FDA has also expanded unannounced foreign inspections, building on a pilot conducted in India and China, so an Indian site should plan for inspection readiness as a standing condition rather than an event.
Is there a separate India to Puerto Rico trade route or tariff?
No, and this follows from the same fact that drives the fee position. Puerto Rico is inside the United States customs territory, so goods arriving from India are United States imports clearing under the harmonised tariff schedule. There is no bilateral India–Puerto Rico trade line, no separate tariff schedule and no separate import licence. The island does publish its own external trade statistics as a distinct series, which recorded USD 16,805 million of pharmaceutical imports in FY2024 including USD 6,503 million from foreign countries, but India is not broken out within them and we did not query United Nations Comtrade or Indian trade databases for this article, so we are not offering an India-to-Puerto Rico figure.
What is the realistic commercial opportunity for an Indian injectable maker?
United States supply resilience rather than island market entry. Puerto Rico exported USD 48,328 million of pharmaceuticals in FY2024, seventy-four per cent of its total exports, from 60 establishments and 13,197 employees, to a resident population estimated at 3,184,835 in July 2025 and declining. It is an export platform competing for the same mainland customer you are. The instructive precedent is 2017, when Hurricane Maria disabled Baxter’s island capacity, worsened a national intravenous fluid shortage, and led FDA to permit temporary imports from Ireland, Australia, Mexico, Canada and Germany. Sterile injectable and biologic capacity remains concentrated on a hurricane-exposed island. A pre-filed, pre-inspected ANDA portfolio in shortage-listed sterile injectables positions you for that, and the USD 15,000 statutory foreign-facility surcharge is the price of entry you should model from day one.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments